The FDA advisory panel met on the 17th to vote for the approval of the emergency use of the second coronavirus vaccine for people aged 18 and above.
The vaccine was developed by Modena Biotechnology in cooperation with the National Institute of Allergy and Infectious Diseases. An analysis released by the FDA recently showed that the effectiveness of the coronavirus vaccine is 96% for people aged 18 to 65 and 86% for people aged 65 and above.
The report said that most of the subjects had symptoms of soreness, fatigue and headache at the injection site after vaccination. Severe allergic reactions rarely occur.
At present, the number of COVID-19 infections, hospitalizations and deaths in the United States have climbed to new highs. As of the evening of the 17th Eastern Time, the cumulative number of confirmed coronavirus cases in the United States exceeded 17.19 million, and the cumulative death toll exceeded 310,000.